1. Cardiovascular Risk Estimation and Eligibility for Statins in Primary Prevention Comparing Different Strategies 
David Nanchen, MD, Arnaud Chiolero, MD, MSc, Jacques Cornuz, MD, MPH, Pedro-Manuel Marques-Vidal, MD, PhD, Mathieu Firmann, MD, Vincent Mooser, MD, Fred Paccaud, MD, MSc, Gérard Waeber, MD, Peter Vollenweider, MD, Nicolas Rodondi, MD, MAS 
American Journal of Cardiology 
Volume 103, Issue 8, Pages (April 2009)
DOI: /j.amjcard
Copyright © 2009 Elsevier Inc. Terms and Conditions

2. Figure 1
Percentages of men (left) and women (right) at estimated high risk according to FRS/ATP-III (diamonds), PROCAM/IAS (triangles), SCORE/ESC (squares and solid lines), and SCORE/ESC with extrapolation (squares and dashed lines).
American Journal of Cardiology  , DOI: ( /j.amjcard )
Copyright © 2009 Elsevier Inc. Terms and Conditions

3. Figure 2
Percentages of participants currently under statin treatment or eligible according to FRS/ATP-III, PROCAM/IAS, and SCORE/ESC with/without extrapolation.
American Journal of Cardiology  , DOI: ( /j.amjcard )
Copyright © 2009 Elsevier Inc. Terms and Conditions

4. Figure 3
(A) Estimated number of CHD deaths potentially adverted and number needed to treat (NNT) to avoid 1 CHD death over 10 years according to FRS/ATP-III (diamonds), PROCAM/IAS (triangles), SCORE/ESC (squares and solid lines), and SCORE/ESC with extrapolation (squares and dashed lines) for 10-year statin treatment, based on full compliance and extrapolated to Swiss men (top) and women (bottom) without CVD 35 to 75 years of age. (B) Estimated number of myocardial infarctions potentially adverted and NNT to avoid 1 myocardial infarction in a 10-year period with full compliance to the different guidelines for 10-year statin treatment, extrapolated to Swiss men without cardiovascular disease 35 to 75 years of age.
American Journal of Cardiology  , DOI: ( /j.amjcard )
Copyright © 2009 Elsevier Inc. Terms and Conditions